Japanese companies have historically had problems getting into the US market because their deal approach in the 1970s was not appropriate for developing drugs. Only TAP succeeded-overcoming many management obstacles.
by Bill Mattson and Steve Cole
In the mid 1970s, when Abbott Laboratoriesand Takeda Chemical Industries Ltd. created the joint venture TAP Pharmaceuticals, both sides...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
